Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders
13 April 2022 - 2:05PM
via NewMediaWire -- Neovasc Inc. (“
Neovasc” or
the “
Company”) (NASDAQ, TSX: NVCN) is pleased to announce
the results of the votes on matters considered at its Annual
General and Special Meeting of Shareholders held on April 12, 2022
in Vancouver, B.C. (the “
Meeting”).
At the Meeting, the shareholders of the Company
(the “Shareholders”) re-elected board members Steven Rubin,
Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko and Fred Colen
to serve in office until the next annual meeting or until their
successors are duly elected or appointed. Detailed results of the
voting in respect of the election of directors are as follows:
Nominee |
Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld |
Steven Rubin |
8,055,190 |
97.73% |
187,258 |
2.27% |
Paul Geyer |
8,070,556 |
97.91% |
171,892 |
2.09% |
Doug Janzen |
8,064,654 |
97.84% |
177,794 |
2.16% |
Norman Radow |
8,057,560 |
97.76% |
184,888 |
2.24% |
Alexei Marko |
8,054,541 |
97.72% |
187,907 |
2.28% |
Fred Colen |
8,127,385 |
98.60% |
115,063 |
1.40% |
At the Meeting, the Shareholders also approved
the Company’s common share consolidation (95.52% of votes cast in
favor) and appointed Grant Thornton LLP (USA), Chartered
Accountants as auditors of the Company.
About Neovasc Inc.
Neovasc is a specialty medical device company
that develops, manufactures and markets products for the rapidly
growing cardiovascular marketplace. Its products include Reducer,
for the treatment of refractory angina, which is not currently
commercially available in the United States and has been
commercially available in Europe since 2015, and TiaraTM for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the United States, Canada, Israel
and Europe. For more information, visit: www.neovasc.com
InvestorsMike CavanaughICR Westwicke Phone:
+1.646.877.9641Mike.Cavanaugh@westwicke.com
MediaSean LeousICR WestwickePhone:
+1.646.677.1839Sean.Leous@westwicke.com
Forward-Looking Statement Disclaimer
Certain statements in this news release contain
forward-looking statements within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws that may not be based on historical fact. When used
herein, the words "expect", "anticipate", "estimate", "may",
"will", "should", "intend," "believe", and similar expressions, are
intended to identify forward-looking statements. Forward-looking
statements may involve but are not limited to, expectations as to
the growing cardiovascular marketplace. Forward-looking statements
are based on estimates and assumptions made by the Company in light
of its experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company's actual
results, performance or achievements to differ materially from
those expressed or implied by the forward looking statements,
including those described in the "Risk Factors" section of the
Company's Annual Report on Form 20-F and in the Management's
Discussion and Analysis for the year ended December 31, 2021
(copies of which may be obtained at www.sedar.com or www.sec.gov).
These factors should be considered carefully, and readers should
not place undue reliance on the Company's forward-looking
statements. The Company has no intention and undertakes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Neovasc (TSX:NVCN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Neovasc (TSX:NVCN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024